Esha Sarkar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Esha Sarkar has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Abbas Ali Mahdi
Era University, Lucknow, India
2 shared publications- Afreen Khan
Department of Biochemistry, Era's Lucknow Medical College and hospital, Era University, Lucknow, Uttar Pradesh, India
2 shared publications - Abbas Ali Mahdi
Department of Biochemistry, King George’s Medical University, Lucknow, India
1 shared publication Afreen Khan
Department of Biochemistry, Era’s Lucknow Medical College & Hospital, Era University, Lucknow, India
1 shared publicationAkanksha Kotiya
Department of Biosciences and Biotechnology, Banasthali Vidyapith, Radha Kishnpura, India
1 shared publication- Anchal Trivedi
Department of Biochemistry, Era's Lucknow Medical College and Hospital Era University Lucknow Uttar Pradesh India
1 shared publication
Latest Publications
- 21 June 2024
- Published by Springer Nature in In Silico Pharmacology
- Vol. 12 (2) , 1-23
The combination of Curcumin and Doxorubicin on targeting PI3K/AKT/mTOR signaling pathway: an in vitro and molecular docking study for inhibiting the survival of MDA-MB-231
The process of tumorigenesis is highly associated with the disruption of cell-cycle regulators and derangement of various signaling pathways, which end up with the inhibition of apoptosis and hyper-activation of survival pathways. The PI3K medicated AKT/mTOR pathway is the widely explained mechanism for cancer cell survival which causes the overexpression of MDM2 and downregulates the p53-BAX mediated apoptotic pathway. Curcumin (CUR), the phyto-compound, derived from Curcuma longa is currently being focused on for its anticancer activities against breast cancer cells, MDA-MB-231, not only because of its minimal cytotoxicity against healthy cells (HEK293) but also because it synergistically sensitizes the activity of Doxorubicin (DOXO) in lower doses, which can be a promising source for complementary drug development. This study aims to investigate the combinatorial effect of CUR and DOXO on PI3K/AKT/mTOR pathway proteins by sequential molecular docking analysis and MD simulation studies. The lower binding affinity of the sequentially docked protein–ligand complex proves the increasing binding affinity of CUR and DOXO in the combinatorial dose. The mRNA expressions of different genes of this pathway are observed and quantified using rt-qPCR, where the decreasing fold change (2−∆∆Ct) indicates the suppression of the AKT/mTOR pathway after co-treatment of CUR and DOXO against MDA-MB-231 cells. These in silico and in vitro findings can be a new horizon for further in vitro and clinical trials of breast cancer treatment.
- 21 June 2024
- Published by Springer Nature in In Silico Pharmacology
- Vol. 12 (2) , 1-23
The combination of Curcumin and Doxorubicin on targeting PI3K/AKT/mTOR signaling pathway: an in vitro and molecular docking study for inhibiting the survival of MDA-MB-231
The process of tumorigenesis is highly associated with the disruption of cell-cycle regulators and derangement of various signaling pathways, which end up with the inhibition of apoptosis and hyper-activation of survival pathways. The PI3K medicated AKT/mTOR pathway is the widely explained mechanism for cancer cell survival which causes the overexpression of MDM2 and downregulates the p53-BAX mediated apoptotic pathway. Curcumin (CUR), the phyto-compound, derived from Curcuma longa is currently being focused on for its anticancer activities against breast cancer cells, MDA-MB-231, not only because of its minimal cytotoxicity against healthy cells (HEK293) but also because it synergistically sensitizes the activity of Doxorubicin (DOXO) in lower doses, which can be a promising source for complementary drug development. This study aims to investigate the combinatorial effect of CUR and DOXO on PI3K/AKT/mTOR pathway proteins by sequential molecular docking analysis and MD simulation studies. The lower binding affinity of the sequentially docked protein–ligand complex proves the increasing binding affinity of CUR and DOXO in the combinatorial dose. The mRNA expressions of different genes of this pathway are observed and quantified using rt-qPCR, where the decreasing fold change (2−∆∆Ct) indicates the suppression of the AKT/mTOR pathway after co-treatment of CUR and DOXO against MDA-MB-231 cells. These in silico and in vitro findings can be a new horizon for further in vitro and clinical trials of breast cancer treatment.
- Open Access
- 26 September 2022
- Published by Elsevier in Cancer Treatment and Research Communications
- Vol. 33, 100641
CRISPR/Cas9 encouraged CAR-T cell immunotherapy reporting efficient and safe clinical results towards cancer
- 26 September 2022
- Published by Elsevier in Cancer Treatment and Research Communications
- Vol. 33, 100641
Open AccessCRISPR/Cas9 encouraged CAR-T cell immunotherapy reporting efficient and safe clinical results towards cancer
- 26 October 2021
- Published by Bentham Science Publishers Ltd. in Current Drug Therapy
- Vol. 16 (3) , 209-223
Restoration of Chemoresistance Mechanism by Novel Drug Therapies in Breast Cancer Cell Lines
Chemoresistance is one of the biggest hurdles while treating cancer clinically. Due to its heterogeneous nature, complications of the chemoresistance mechanisms of breast cancer cannot be completely elucidated. Existing mechanisms of main-line drug treatment can slow down the process of malignancy with part and parcel called drug resistance. The combinatorial effect of several chemotherapeutic drugs, targeting different pathways at the same time, can work efficiently, yet the toxicity and drug-drug interaction remain intact. To overcome this hurdle, a number of strategies have been discovered, such as novel agents, drug carriers, and combination treatment, etc., which target mediated drug delivery systems; nanomedicine and the use of phytocompounds can transfer the drug particularly to the cancerous cells with minimal side effects to the neighboring healthy cells. The cell cycle checkpoint proteins and genes induced to the deranged cells can inhibit the resistance mechanism towards the drug. Modification of cell signaling pathways can also help to treat breast cancer chemoresistance mechanisms in the long run. This article reviews the execution and onset of chemoresistance in various cancers and discusses potential therapeutic approaches to deal with the resistance mechanism. This review summarizes the possible mechanisms and signaling pathways causing chemoresistance in breast cancer cell lines and discusses alternative therapy to overcome this issue under pre-clinical and clinical infrastructure.
- 26 October 2021
- Published by Bentham Science Publishers Ltd. in Current Drug Therapy
- Vol. 16 (3) , 209-223
Restoration of Chemoresistance Mechanism by Novel Drug Therapies in Breast Cancer Cell Lines
Chemoresistance is one of the biggest hurdles while treating cancer clinically. Due to its heterogeneous nature, complications of the chemoresistance mechanisms of breast cancer cannot be completely elucidated. Existing mechanisms of main-line drug treatment can slow down the process of malignancy with part and parcel called drug resistance. The combinatorial effect of several chemotherapeutic drugs, targeting different pathways at the same time, can work efficiently, yet the toxicity and drug-drug interaction remain intact. To overcome this hurdle, a number of strategies have been discovered, such as novel agents, drug carriers, and combination treatment, etc., which target mediated drug delivery systems; nanomedicine and the use of phytocompounds can transfer the drug particularly to the cancerous cells with minimal side effects to the neighboring healthy cells. The cell cycle checkpoint proteins and genes induced to the deranged cells can inhibit the resistance mechanism towards the drug. Modification of cell signaling pathways can also help to treat breast cancer chemoresistance mechanisms in the long run. This article reviews the execution and onset of chemoresistance in various cancers and discusses potential therapeutic approaches to deal with the resistance mechanism. This review summarizes the possible mechanisms and signaling pathways causing chemoresistance in breast cancer cell lines and discusses alternative therapy to overcome this issue under pre-clinical and clinical infrastructure.
- 1 December 2019
- Published by Era's Lucknow Medical College and Hospital in Era's Journal of Medical Research
- Vol. 6 (2) , 124-130
CURCUMA LONGA: THE GOLDEN SPICE, POWERFULANTICANCER AGENT IN BREAST CANCER TREATMENT
- 1 December 2019
- Published by Era's Lucknow Medical College and Hospital in Era's Journal of Medical Research
- Vol. 6 (2) , 124-130
CURCUMA LONGA: THE GOLDEN SPICE, POWERFULANTICANCER AGENT IN BREAST CANCER TREATMENT